CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2011-07-18): Pitavastatin may enhance antivirals in some hepatitis C patients

Drug & Device Development

Pitavastatin may enhance antivirals in some hepatitis C patients

Last Updated: 2011-07-18 14:07:25 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Lipid-lowering pitavastatin (Livalo) might improve viral clearance when used alongside interferon and ribavirin in chronic hepatitis C patients with abnormal lipid metabolism, a new pilot study from Japan shows.

Rates of sustained virologic response (i.e., undetectable HCV-RNA 24 weeks after treatment end) were 67% in the pitavastatin group vs. 48% in controls.

The improvement wasn't statistically significant, but the randomized trial included only 42 patients, the researchers said in a letter published online June 29th in the Journal of Hepatology.

Coauthor Dr. Shuhei Yoshida, of Beth Israel Deaconess Medical Center in Boston, told Reuters Health by email that the study was confined to patients with lipid abnormalities and so the results don't apply to HCV-infected patients with normal lipid metabolism.

Pitavastatin lowers patients' insulin resistance -- and the researchers point out that high insulin resistance in chronic hepatitis C impairs the response to therapy.

All of the patients had HCV genotype 1b and were receiving pegylated Interferon 2b and ribavirin. Twenty-one patients received add-on pitavastatin (1 to 2 mg/day) for 48 weeks while an equal number continued with the standard therapy.

The initial viral load was greater than 5.0 log IU/ml.

In the pitavastatin group, the viral levels were undetectable in 29% at 4 weeks, 57% at 8 weeks, 81% at 12 weeks, 86% at 24 weeks, and 86% at 48 weeks. The corresponding values in controls were 5%, 33%, 48%, 62% and 67%, respectively.

There were no significant adverse reactions with pitavastatin.

Just how pitavastatin acts to limit HCV replication isn't clear, Dr. Yoshida admitted in his email.

The researchers plan further studies with larger populations and more varied patients.

SOURCE: http://bit.ly/rlHiym

J Hepatology 2011

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.